个人简历

Education Background
1994.09-1999.07
M.B. in Chemical Analysis,
Shandong Medical University.
1999.09-2002.07
M.S. in Biochemistry and Molecular Biology,
Fudan University.
2002.09-2004.09
Mphil in Clinical Oncology,
The Chinese University of HongKong.
2004.10-2009.09
PhD in Cancer Biology,
University College London.
Working experiences
2012.4-
Professor,
Harbin Institute of Technology
2009.11-2012.1
Postdoctoral Molecular Biologist,
University of Oxford
2009.6-2009.11
Researcher scientist,
University of Oxford
Research Funding
1 哈尔滨工业大学人才引进科研启动经费,肿瘤发病机制以及生物治疗方法的研究,2014.01-2016.12
Harbin Institute of Technology talent introduction program funds;
2 深圳市博泰生物医学科技发展有限公司,抗原致敏DC-CIK细胞对肾癌A498细胞系的杀伤作用机制,2014.01-2016.06
Joint Fund with Shenzhen Botai Biomedical Technology Co. Ltd
3 国家自然科学基金委青年基金,2014.01-2016.12
The National Natural Science Foundation of China (NSFC);
4 教育部博士点基金,2014.01-2016.12
Doctoral Fund of Ministry of Education of China;
5 黑龙江省自然科学基金 ,2014.01-2015.12
The National Natural Science Foundation of Heilongjiang Province;
6. 哈尔滨市科技创新人才研究专项基金, 2014.07-2016.06
Harbin special fund for scientific and technological innovation;
7 哈工大理工医交叉学科基础研究培育计划, 2014.01-2015.12
Harbin Institute of Technology interdisplinary funds.
8 深圳科技与创新委员会基础研究项目, 2015.01-2017.12
Basic Research Program of Science and Innovation Commission Foundation of Shenzhen.
Lectures
Undergraduate: 生物统计学 (Biostatistics)
Master student: 生命科学研究进展前沿(Progress and Fronts of Research of Life Sciences)
Undergraduate: 生物学基础与应用
International student: cancer
Open positions
1. 硕士招生:
每年计划招收硕士2名 ，研究方向：
(1). 癌基因以及抑癌基因在肿瘤发生,发展过程中的作用。
(2). 癌基因以及抑癌基因在不同的刺激因子引发的细胞凋亡过程中的作用。
1-2 Master positions are available in the laboratory of Dr. Ying HU to study molecular and cellular mechanisms of carcinogenesis. The candidates with background in biology or medicine are highly encouraged to apply. If you are interested, please contact Dr. Ying HU at huying@hit.edu.cn

2. 博士招生:
每年计划招收博士生1－2名，研究方向：
(1). 癌基因以及抑癌基因在肿瘤发生,发展过程中的作用。
(2). 癌基因以及抑癌基因在不同的刺激因子引发的细胞凋亡过程中的作用。
(3). 基础研究结果对肿瘤诊断和治疗方面的指导意义。
1-2 PhD positions are available in the laboratory of Dr. Ying HU to study molecular and cellular mechanisms of carcinogenesis. The candidates with background in biology or medicine are highly encouraged to apply. If you are interested, please contact Dr. Ying HU at huying@hit.edu.cn

3. 博士后 (postdoctoral research fellow)：
计划招收博士后1-2名, 要求:
优先考虑具有分子细胞生物学博士背景的应聘者。
能够在PI的指导下展独立开展课题研究，并指导及帮助研究生；
能够阅读理解英文专业文献，掌握基本细胞生物学，生物化学，分子生物学实验技能。
有在SCI期刊上发表第一作者论文的经历。
在开展部分独立实验的同时，协助实验室的日常运转。
工作积极、善于交流、学风严谨且具有高度责任心和团队精神。
1-2 Postdoc positions are available to study molecular and cellular mechanisms of carcinogenesis in the lab. Candidates should be experienced in molecular biology and be able to design and perform experiments independently and effectively, with appropriate support. Desired experimental skills include sub-cloning into plasmids, cell culture and transfection of mammalian cells, analysis of mRNA and protein expression, immunohistochemistry and fluorescence microscopy. Prior experience with translational or posttranslational modulation of gene expression would be advantageous. Salary will be according to skills and experience in the areas relevant to the project. Applications including CV, publication list, description and results of previous research activities and the names and contact details of at least two references should be sent to E-mail。

研究领域

胡颖教授的研究室主要进行肿瘤生物学领域特别是对癌基因和抑癌基因功能的探讨。p53基因是在人类肿瘤中最常见的突变基因。50％以上的肿瘤含有p53基因的突变，而野生型p53的肿瘤也往往伴有p53信号传导通路组份的缺陷。明确p53的生物学功能及其调控机制对于深入理解肿瘤发生的分子机制至关重要。胡颖博士的研究兴趣主要是探讨p53信号的分子机制，特别是解剖p53家族成员与其上游调控蛋白，如ASPPs，之间的相互作用，在分子和细胞水平，利用肿瘤细胞模型和临床人体癌组织样本进行肿瘤分子机制的研究。同时关注ASPPs基因表达调控的机制，并对该组蛋白的未知功能进行探讨。目前实验室使用的方法和技术主要包括体外细胞培养，MTT，Western印迹，RT-PCR，流式细胞仪，分子克隆，软琼脂和其他多种分子和细胞生物学工具，以为人类恶性疾病提供重要的生物标志物和治疗靶点为己任。
Professor Ying Hu’s laboratory mainly focused on cancer biology specifically in the field of proto-oncogene and tumor suppressor’s functions. p53 is the most frequently-mutated gene in human tumors. Over 50% of all tumors and almost every type of tumor contain p53 mutations, whereas wild type p53 tumors are often accompanied with the defects in p53 signaling components. No doubt, revealing p53’s functions and its regulatory mechanisms is critical for understanding the molecular mechanisms of oncogenesis. Dr. HU’s research interest is to investigate p53 signaling and particularly to dissect the interactions of p53 family members with other upstream regulatory proteins, such as ASPPs. Her group is focused on the translational and posttranslational regulatory mechanisms of ASPPs. Another paradigm of their work is to reveal p53-independent biological functions of ASPPs. The research in the lab is carried out at molecular and cellular levels using both cancer cells models and clinical human cancer tissue samples. The methods and technologies used in her current lab include in vitro cell culture, MTT, Western Blotting, FACS, RT-PCR, molecular cloning, soft agar assay and many other molecular and cellular tools. The goal of laboratory is to develop clinically relevant biomarkers and therapeutic targets for human malignancy diseases.
氧化应激对肿瘤发生，发展以及耐药的影响机制
癌基因和抑癌基因的功能及调控机制
非编码RNA在肿瘤中的作用及机制

The impact of oxidative stresses on the development of cancers and chemotherpeutic responses
The functions and regualtory mechanisms of oncogen and tumour suppressors
The functions of lncRNA in cancer"Biological functions of proto-oncogene and tumor suppressor"

近期论文

1. Ge W#, Zhao K#, Wang X, Li H, Yu M, He M, Xue X, Zhu Y, Zhang C, Cheng Y, Jiang S, Hu Y*. iASPP Is an Antioxidative Factor and Drives Cancer Growth and Drug Resistance by Competing with Nrf2 for Keap1 Binding. Cancer Cell. 2017 Nov 13;32(5):561-573.e6. Featured artical
2. Zhao K, Wang X, Xue X, Li L, Hu Y*. A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers. PLoS Biol. 2020 Mar 23;18(3): e3000666.
3. Wang X, Li L, Zhao K, Lin Q, Li H, Xue X, Ge W, He H, Liu D, Xie H, Wu Q, Hu Y*. A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth. Cell Death Differ. 2020 Apr;27(4):1431-1446. CDDPress Monthly Top Picks
4. Wang X, Wang Y, Li L, Xue X, Xie H, Shi H, Hu Y*. A lncRNA coordinates with Ezh2 to inhibit HIF-1α transcription and suppress cancer cell adaption to hypoxia. Oncogene. 2020 Feb;39(9):1860-1874.
5. Li H#, Zhang W#, Zhao K, Zhao D, Zheng S, Hu Y*. A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells. J Biol Chem. 2020 Mar 20;295(12):4049-4063
6. Li H#, Wang X#, Zhang C, Cheng Y, Yu M, Zhao K, Ge W, Cai A, Zhang Y, Han F, Hu Y*. HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma. Cancer Lett. 2018 Sep 28;432:121-131.
7. Wang X, Cheng Y, Zhu Y, Li H, Ge W, Wu X, Zhao K, Yuan J, Li Z, Jiang S, Han Z, Jiang Q, Wu Q, Liu T, Zhang C*, Yu M*, Hu Y*. Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation. Int J Cancer. 2017 Oct 1;141(7):1422-1433.
8. Zhao K, Yu M, Zhu Y, Liu D, Wu Q, Hu Y*. EGR-1/ASPP1 inter-regulatory loop promotes apoptosis by inhibiting cyto-protective autophagy. Cell Death Dis. 2017 Jun 8;8(6): e2869.
9. Wang X, Yu M, Zhao K, He M, Ge W, Sun Y, Wang Y, Sun H, Hu Y*. Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2. Cell Death Dis. 2016 Dec 8;7(12): e2517.
10. Kunming Zhao and Ying Hu*. Microbiome harbored within tumors: a new chance to revisit our understanding of cancer pathogenesis and treatment. Signal Transduct Target Ther. 2020 Jul 29;5(1):136.
Other Publicaitons
1. Dedei？ Z#, Sutendra G#, Hu Y#, Chung K, Slee EA, White MJ, Zhou FY, Goldin RD, Ferguson DJP, McAndrew D, Schneider JE, Lu X. Cell autonomous role of iASPP deficiency in causing cardiocutaneous disorders. Cell Death Differ. 2018 Jul;25(7):1289-1303.
2. Shao LN, Zhang ST, Yu WJ, Zhou SH, Duan Y, Pan LZ, Wang N, Hu Y*. HLA-A, HLA-B, HLA-DRB1 allele and haplotype frequencies of 14,529 Chinese Han bone marrow donors living in Dalian, China. Int J Immunogenet. 2016 Apr;43(2):79-85.
3. Li Z, Liu J, Hu Y, Howard KA, Li Z, Fan X, Chang M, Sun Y, Besenbacher F, Chen C, Yu M. Multimodal Imaging-Guided Antitumor Photothermal Therapy and Drug Delivery Using Bismuth Selenide Spherical Sponge. ACS Nano. 2016 Oct 25;10(10):9646-9658.
4. Li Z, Hu Y, Chang M, Howard KA, Fan X, Sun Y, Besenbacher F, Yu M. Highly porous PEGylated Bi2S3 nano-urchins as a versatile platform for in vivo triple-modal imaging, photothermal therapy and drug delivery. Nanoscale. 2016 Sep 21;8(35):16005-16.
5. Hu Y*, Ge W, Wang X, Sutendra G, Zhao K, Dedei？ Z, Slee EA, Baer C, Lu X*. Caspase cleavage of iASPP potentiates its ability to inhibit p53 and NF-κB. Oncotarget. 2015 Dec 15;6(40):42478-90.
6. Sun H, Ge W, Gao X, Wang S, Jiang S, Hu Y*, Yu M*, Hu S*. Apoptosis-Promoting Effects of Hematoporphyrin Monomethyl Ether-Sonodynamic Therapy (HMME-SDT) on Endometrial Cancer. PLoS One. 2015 Sep 14;10(9):e0137980.
7. Li Z, Hu Y, Howard KA, Jiang T, Fan X, Miao Z, Sun Y*, Besenbacher F*, Yu M*. Multifunctional Bismuth Selenide Nanocomposites for Antitumor Thermo-Chemotherapy and Imaging. ACS Nano. 2016 Jan 26;10(1):984-97.
8. Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X*. Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell. 2016 Nov 14;30(5):822-823.
9. Mario Notari#，Ying Hu#，Sofia Koch，Min Lu，Indrika Ratnayaka，ShanZhong，Caroline Baer，Anna Pagotto，Robert Goldin，Victoria Salter，Eleonora Candi，Gerry Melino，and Xin Lu*. iASPP prevents premature cellular senescence and is required for normal epithelial stratification. Proc Natl Acad Sci. 2011. 108(40): 16645–16650. （# co-first author）
10. Ying Hu, Pang E, Lai PB, Squire JA, MacGregor PF, Beheshti B, Albert M, Leung TW, Wong N*. Genetic alterations in doxorubicin-resistant hepatocellular carcinoma cells: a combined study of spectral karyotyping, positional expression profiling and candidate genes. Int J Oncol. 2004. 25(5):1357-1364.
11. Mario Notari，Ying Hu，Gopinath Sutendra, Zinaida Dedeic, Min Lu, Laurent Dupays, Arash Yavari, Carolyn Carr, Shan Zhong, Aaisha Opel, Andrew Tinker, Kieran Clarke, Hugh Watkins, David Ferguson, David Kelsell, Sofia de Noronha, Mary Sheppard, Mike Hollinshead, Timothy J Mohun and Xin Lu*. iASPP: A Novel Desmosome Regulator and its Deficiency Causes Arrhythmogenic Right Ventricular Cardiomyopathy. Proc Natl Acad Sci. 2015. Feb 17. pii: 201408111.